Enliven Therapeutics, Inc. (ELVN)

USD 15.73

(5.5%)

Market Cap (In USD)

770.83 Million

Revenue (In USD)

-

Net Income (In USD)

-71.58 Million

Avg. Volume

273.62 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
10.9-30.03
PE
-8.32
EPS
-1.89
Beta Value
0.931
ISIN
US29337E1029
CUSIP
29337E102
CIK
1672619
Shares
49004400.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Samuel S. Kintz M.B.A.
Employee Count
-
Website
https://www.enliventherapeutics.com
Ipo Date
2020-03-12
Details
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.